Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform integrates the company's proprietary PDAOAI technology with advanced robotics provided through a collaboration with TechForce Robotics, aiming to support pharmaceutical, biotechnology, and advanced therapeutics companies in modernizing their manufacturing operations.
According to the company, the platform is designed to handle electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions, and process monitoring. This move reflects a growing trend in the industry toward AI-driven workflows and intelligent automation to enhance efficiency and compliance in drug manufacturing.
In addition to the platform launch, Oncotelic will showcase progress with its Deciparticle nanomedicine platform, including SAPU003, a clinical-stage intravenous everolimus program currently being evaluated in a Phase 1b study. The company’s focus on oncology and immunotherapy products addresses high-unmet-need cancers and rare pediatric indications.
Oncotelic’s CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued U.S. patents. The company also owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership, which is advancing its own pipeline of drug candidates that complement Oncotelic’s strategic position in oncology and rare disease therapeutics.
The PDAOAI platform underpins the company’s GMP manufacturing services and its ongoing joint development work with TechForce Robotics, Oncotelic’s strategic robotics and automation partner. TechForce Robotics, the operating brand of Nightfood Holdings, Inc., designs and deploys purpose-built robotics and automation solutions for pharmaceutical manufacturing applications.
For more information about Oncotelic Therapeutics, visit www.oncotelic.com. For details on TechForce Robotics, visit www.techforcerobotics.com. The full press release is available at https://ibn.fm/upnBW.
The implications of this announcement are significant for the pharmaceutical manufacturing sector, as AI-powered platforms can reduce errors, accelerate production timelines, and improve regulatory compliance. By combining AI with robotics, Oncotelic aims to offer a comprehensive solution that addresses key pain points in GMP manufacturing, potentially setting a new standard for the industry.
About Oncotelic Therapeutics: Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.
About TechForce Robotics: TechForce Robotics designs, develops, and deploys purpose-built robotics and automation solutions for service, hospitality, and pharmaceutical manufacturing applications, in partnership with global robotics and manufacturing leaders.
